ArticleHealth science reports2026
Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03200184 (Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis C virus (HCV) infection is one of the leading causes of liver-related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV infection among family members of HCV-positive index cases, within related risk factors in them. Additionally, the study evaluated the therapeutic efficacy of the combination drug Sovodak (sofosbuvir-daclatasvir) based on HCV genotype. Methods: This study is a descriptive cross-sectional study conducted on the families of individuals with Hepatitis C (12 people) within the Guilan cohort population. Twenty family members of HCV-positive individuals were enrolled. Data were collected using structured questionnaires that included socio-demographic and clinical information. Blood samples were drawn from each participant, and sera were separated for serological analysis. HCV antibody-positive samples were assessed by HCV-RNA detection. Subsequently, positive samples underwent HCV genotyping. Then, HCV-positive individuals were referred in Phase 3 clinical trial with ID: NCT03200184. for treatment and follow-up. Treatment consisted of Sovodak (a combination of sofosbuvir 400 mg and daclatasvir 60 mg). The clinical and diagnostic effectiveness of the treatment was evaluated 12 weeks after therapy initiation. Results: Out of the total cases, two were HCV antibody positive, and one of them was a 13-year-old girl who tested positive for HCV RNA by PCR. Her genotype was 1a, which matched her mother's genotype. This patient was successfully treated with Sovodak. The post-treatment HCV RNA results were negative, indicating a sustained virologic response (SVR = 12). Conclusion: Evidence of intrafamilial transmission was observed in this study, its frequency was extremely low and statistically negligible. Shared household items, although seemingly unlikely, such as toothpaste, may serve as a potential route of transmission within families, independent of direct interpersonal contact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.